Analyzing Dynamic Changes of Laboratory Indexes in Patients with Acute Heart Failure Based on Retrospective Study

Table 1

Comparisons of baseline characteristics between AHF patients with different clinical outcomes.

	Control ()	Adverse event ()	value
Age (years), median (Q1–Q3)	67 (52–77)	74 (61–80)	0.006
Male, (%)	109 (58.0)	55 (57.3)	0.912
NYHA III to IV, (%)	152 (80.9)	67 (69.8)	0.036
History
CAD, (%)	98 (52.1)	67 (35.6)	0.004
MI, (%)	77 (41.0)	39 (40.6)	0.957
Hypertension, (%)	133 (70.7)	68 (70.8)	0.988
Diabetes, (%)	72 (38.3)	40 (41.7)	0.583
Arrhythmia, (%)	64 (34.0)	36 (37.5)	0.564
COPD, (%)	37 (19.7)	20 (20.8)	0.819
CKD, (%)	64 (34.0)	53 (55.2)	0.001
Stroke, (%)	24 (12.8)	28 (29.2)	0.001
Vital signs
RR (bpm), median (Q1–Q3)	18 (18–20)	18 (18–21)	0.357
Pulse (bpm), mean ± SD			0.656
SBP (mmHg), mean ± SD			0.076
DBP (mmHg), mean ± SD			0.005
Lab indexes
LVEF (%), mean ± SD			0.114
NT-proBNP (pg/mL), median (Q1–Q3)	7024 (2729–13923)	9922 (3825–29632)	0.017
TNT (ng/mL), median (Q1–Q3)	0.052 (0.026–0.194)	0.104 (0.042–0.447)	0.002
CRP (mg/dL), median (Q1–Q3)	1.69 (0.40–5.77)	4.20 (1.40–14.00)	<0.001
eGFR (mL/min), median (Q1–Q3)	73 (32–98)	44 (21–80)	0.004
CK (U/L), median (Q1–Q3)	98.9 (53.8–171.1)	87 (46.8–169.5)	0.251
LDH (U/L), median (Q1–Q3)	259.5 (209.6–334.2)	286.8 (220.1–443.5)	0.077
Glucose (mmol/L), median (Q1–Q3)	8.88 (6.25–12.23)	8.06 (6.13–10.54)	0.179

AHF: acute heart failure; CAD: coronary artery disease; CK: creatine kinase; CKD: chronic kidney disease; CK-MB: creatine kinase isoenzyme; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; LDH: lactic dehydrogenase; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NT-proBNP: N-terminal probrain natriuretic peptide; NYHA: New York Heart Association; Q: quartile; RR: respiratory rate; SBP: systolic blood pressure; and TNT: troponin T.